These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37065248)

  • 1. Pathological features of African horse sickness virus infection in IFNAR
    Jones LM; Hawes PC; Salguero FJ; Castillo-Olivares J
    Front Vet Sci; 2023; 10():1114240. PubMed ID: 37065248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes.
    Lulla V; Lulla A; Wernike K; Aebischer A; Beer M; Roy P
    J Virol; 2016 Aug; 90(16):7405-7414. PubMed ID: 27279609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the virulence of serotypes 4 and 9 of African horse sickness virus in IFNAR(-/-), Balb/C and 129 Sv/Ev mice.
    de la Grandière MA; Dal Pozzo F; Tignon M; Zonta W; Thiry D; Mauroy A; Mathijs É; Caij AB; Saegerman C; Thiry É
    Vet Microbiol; 2014 Dec; 174(3-4):322-332. PubMed ID: 25458420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
    Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
    Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
    Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
    Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
    Castillo-Olivares J; Calvo-Pinilla E; Casanova I; Bachanek-Bankowska K; Chiam R; Maan S; Nieto JM; Ortego J; Mertens PP
    PLoS One; 2011 Jan; 6(1):e16503. PubMed ID: 21298069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
    van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
    J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine mRNA Expression Profile in Target Organs of IFNAR (-/-) Mice Infected with African Horse Sickness Virus.
    Calvo-Pinilla E; Jiménez-Cabello L; Utrilla-Trigo S; Illescas-Amo M; Ortego J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR
    O'Kennedy MM; Coetzee P; Koekemoer O; du Plessis L; Lourens CW; Kwezi L; du Preez I; Mamputha S; Mokoena NB; Rutkowska DA; Verschoor JA; Lemmer Y
    Vaccine; 2022 Aug; 40(35):5160-5169. PubMed ID: 35902279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
    Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
    Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
    Alberca B; Bachanek-Bankowska K; Cabana M; Calvo-Pinilla E; Viaplana E; Frost L; Gubbins S; Urniza A; Mertens P; Castillo-Olivares J
    Vaccine; 2014 Jun; 32(29):3670-4. PubMed ID: 24837765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.
    Rutkowska DA; Mokoena NB; Tsekoa TL; Dibakwane VS; O'Kennedy MM
    BMC Vet Res; 2019 Dec; 15(1):432. PubMed ID: 31796116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
    van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
    Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.
    O'Kennedy MM; Roth R; Ebersohn K; du Plessis LH; Mamputha S; Rutkowska DA; du Preez I; Verschoor JA; Lemmer Y
    PLoS One; 2024; 19(4):e0301340. PubMed ID: 38625924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.
    de la Poza F; Calvo-Pinilla E; López-Gil E; Marín-López A; Mateos F; Castillo-Olivares J; Lorenzo G; Ortego J
    PLoS One; 2013; 8(7):e70197. PubMed ID: 23894615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
    Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
    Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of introducing African horse sickness virus into the Netherlands by international equine movements.
    de Vos CJ; Hoek CA; Nodelijk G
    Prev Vet Med; 2012 Sep; 106(2):108-22. PubMed ID: 22341773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.